Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo de Braud

Showing results (11-20 of 497) with videos related to

Pageof 50
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Adjuvant chemotherapy in new stage II pN0 non-small cell lung cancer: a new issue for a case-by-case decision making processTommaso De Pas, Filippo de Braud, Giulia Veronesi
The Oncologist|October 18, 2012
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancerEduardo Díaz-Rubio, Filippo Pietrantonio, Filippo de Braud
Current Opinion in Oncology|July 12, 2018
Immunotherapy-based combinations: an updateGiovanni Fucà, Filippo de Braud, Massimo Di Nicola
Frontiers in Immunology|September 22, 2015
Lymphoma Immunotherapy: Current StatusRoberta Zappasodi, Filippo de Braud, Massimo Di Nicola
Cancer Biology & Therapy|November 21, 2013
First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profileRoberto Iacovelli, Elena Verzoni, Filippo De Braud, et al.
The Lancet. Oncology|February 15, 2018
Combination therapies for patients with metastatic renal cell carcinomaGiuseppe Procopio, Raffaele Ratta, Filippo de Braud, et al.
The Lancet. Oncology|December 3, 2014
FOLFIRI with cetuximab or bevacizumab: FIRE-3Filippo Pietrantonio, Roberto Iacovelli, Maria Di Bartolomeo, et al.
Seminars in Oncology|November 29, 2015
Better Together: Targeted Combination Therapies in Breast CancerElisa Zanardi, Giacomo Bregni, Filippo de Braud, et al.
Leukemia & Lymphoma|June 19, 2004
Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphomaLucia Loni, Filippo De Braud, Pier Luigi Zinzani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit RatioAlice Indini, Massimo Di Nicola, Michele Del Vecchio, et al.
Pageof 50

Showing results (11-20 of 497) with videos related to

Sort By:
Pageof 50
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Adjuvant chemotherapy in new stage II pN0 non-small cell lung cancer: a new issue for a case-by-case decision making processTommaso De Pas, Filippo de Braud, Giulia Veronesi
The Oncologist|October 18, 2012
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancerEduardo Díaz-Rubio, Filippo Pietrantonio, Filippo de Braud
Current Opinion in Oncology|July 12, 2018
Immunotherapy-based combinations: an updateGiovanni Fucà, Filippo de Braud, Massimo Di Nicola
Frontiers in Immunology|September 22, 2015
Lymphoma Immunotherapy: Current StatusRoberta Zappasodi, Filippo de Braud, Massimo Di Nicola
Cancer Biology & Therapy|November 21, 2013
First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profileRoberto Iacovelli, Elena Verzoni, Filippo De Braud, et al.
The Lancet. Oncology|February 15, 2018
Combination therapies for patients with metastatic renal cell carcinomaGiuseppe Procopio, Raffaele Ratta, Filippo de Braud, et al.
The Lancet. Oncology|December 3, 2014
FOLFIRI with cetuximab or bevacizumab: FIRE-3Filippo Pietrantonio, Roberto Iacovelli, Maria Di Bartolomeo, et al.
Seminars in Oncology|November 29, 2015
Better Together: Targeted Combination Therapies in Breast CancerElisa Zanardi, Giacomo Bregni, Filippo de Braud, et al.
Leukemia & Lymphoma|June 19, 2004
Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphomaLucia Loni, Filippo De Braud, Pier Luigi Zinzani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit RatioAlice Indini, Massimo Di Nicola, Michele Del Vecchio, et al.
Pageof 50